Trials / Unknown
UnknownNCT04566055
Assessing AlloSure Dd-cfDNA Monitoring Insights of Renal Allografts With Longitudinal Surveillance
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (actual)
- Sponsor
- CareDx · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Accepted
Summary
Prospective Observational Multicenter Cohort. External validation of donor derived cell free DNA in Renal Transplantation. Assessing performance of dd-cfDNA as a surveillance tool and its association with clinical outcomes. Outcomes include formation of de-novo DSA, eGFR decline, performance of AlloSure dd-cfDNA in Allograft rejection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | AlloSure | Patients will receive donor-derived cell-free DNA testing for surveillance and for-cause. |
Timeline
- Start date
- 2019-03-01
- Primary completion
- 2020-10-01
- Completion
- 2020-10-01
- First posted
- 2020-09-28
- Last updated
- 2020-10-05
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04566055. Inclusion in this directory is not an endorsement.